{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:06:55Z","timestamp":1773274015552,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA 008748"],"award-info":[{"award-number":["P30 CA 008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Locoregional failure is common after subtotal resection in high\u2010risk neuroblastoma. Although a dose of 21\u00a0Gy radiation therapy (RT) is standard for treatment of high\u2010risk neuroblastoma after gross total resection, the dose needed for local control of patients with gross residual disease at the time of RT is unknown. We sought to evaluate local control after 21\u201336\u00a0Gy RT in patients with high\u2010risk neuroblastoma undergoing subtotal resection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients with high\u2010risk neuroblastoma who received RT to their primary site from 2000 to 2016 were reviewed. Of the 331 patients who received consolidative RT to their primary site, 19 (5.7%) underwent subtotal resection and were included in our analysis. Local failure (LF) was correlated with biologic prognostic factors and dose of RT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median follow\u2010up among surviving patients was 6.0 years. Median RT dose was 25\u00a0Gy (range, 21\u00a0Gy\u201336\u00a0Gy). The 5\u2010year cumulative incidence of LF among all patients was 17.2%. LF at 5 years was 30% in those who received &lt;30\u00a0Gy versus 0% in those who received 30\u201336\u00a0Gy (<jats:italic>P\u00a0=\u00a0<\/jats:italic>0.12). There was a trend towards improved local control in patients with tumor size \u226410\u00a0cm at diagnosis (<jats:italic>P\u00a0=\u00a0<\/jats:italic>0.12). The 5\u2010year event\u2010free and overall survival were 44.9% and 68.7%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After subtotal resection, patients who received less than 30\u00a0Gy had poor local control. Doses of 30\u201336\u00a0Gy are likely needed for optimal control of gross residual disease at the time of consolidative RT in high\u2010risk neuroblastoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.27009","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T12:26:52Z","timestamp":1519302412000},"source":"Crossref","is-referenced-by-count":21,"title":["Dose\u2010escalation is needed for gross disease in high\u2010risk neuroblastoma"],"prefix":"10.1002","volume":"65","author":[{"given":"Dana L.","family":"Casey","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York City New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian H.","family":"Kushner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York City New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai\u2010Kong V.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York City New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakeel","family":"Modak","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Memorial Sloan Kettering Cancer Center  New York City New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"LaQuaglia","sequence":"additional","affiliation":[{"name":"Department of Surgery Memorial Sloan Kettering Cancer Center  New York City New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5234-4134","authenticated-orcid":false,"given":"Suzanne L.","family":"Wolden","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center  New York City New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.5.789"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20091"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1082-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.05.020"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2821"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.10.069"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.07.019"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2003.11.028"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)04506-6"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.101"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3468(91)90686-N"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24350"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.08.035"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-006-1498-8"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.27009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:51:21Z","timestamp":1695513081000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.27009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1002\/pbc.27009"],"URL":"https:\/\/doi.org\/10.1002\/pbc.27009","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"article-number":"e27009"}}